{"id":7453,"date":"2025-03-25T08:49:00","date_gmt":"2025-03-25T07:49:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/"},"modified":"2025-03-25T08:49:00","modified_gmt":"2025-03-25T07:49:00","slug":"nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/","title":{"rendered":"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien"},"content":{"rendered":"
\n

Nanexa meddelar att samtliga patienter nu inkluderats i den fj\u00e4rde och sista doskohorten i fas I-studien av NEX-22, en enm\u00e5nadsformulering av liraglutid.<\/strong><\/p>\n<\/div>\n

\n

NEX-22 \u00e4r en ny lovande behandling som utvecklas f\u00f6r typ 2-diabetes. Fas I-studien syftar till att utv\u00e4rdera farmakokinetiken, s\u00e4kerheten och tolerabiliteten av NEX-22. Inkluderingen av de sista patienterna i den fj\u00e4rde doskohorten markerar en viktig milstolpe i utvecklingen av denna enm\u00e5nads liraglutidprodukt.<\/p>\n

"Vi \u00e4r mycket n\u00f6jda med de framsteg vi har gjort i fas I-studien av NEX-22," s\u00e4ger David Westberg, vd p\u00e5 Nanexa. "Den positiva s\u00e4kerhets- och tolerabilitetsutv\u00e4rderingen av den f\u00f6rsta patienten i den fj\u00e4rde doskohorten bekr\u00e4ftar att vi kan slutf\u00f6ra studien med \u00e5terst\u00e5ende patienter enligt plan och ta ytterligare steg mot att erbjuda en ny behandlingsm\u00f6jlighet f\u00f6r typ 2-diabetespatienter."<\/p>\n

Dessa data kommer att vara st\u00f6djande inf\u00f6r start av n\u00e4sta kliniska studie och st\u00e4rka bolagets aff\u00e4rsaktiviteter, vilket ytterligare understryker potentialen hos NEX-22 som en ny effektiv behandling.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa meddelar att samtliga patienter nu inkluderats i den fj\u00e4rde och sista doskohorten i fas I-studien av NEX-22, en enm\u00e5nadsformulering av liraglutid.<\/p>\n","protected":false},"template":"","class_list":["post-7453","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa meddelar att samtliga patienter nu inkluderats i den fj\u00e4rde och sista doskohorten i fas I-studien av NEX-22, en enm\u00e5nadsformulering av liraglutid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\\\/\",\"name\":\"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-03-25T07:49:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB","og_description":"Nanexa meddelar att samtliga patienter nu inkluderats i den fj\u00e4rde och sista doskohorten i fas I-studien av NEX-22, en enm\u00e5nadsformulering av liraglutid.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/","name":"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-03-25T07:49:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-doserar-de-sista-patienterna-med-30-mg-liraglutid-i-nex-22-01-studien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa doserar de sista patienterna med 30 mg liraglutid i NEX-22-01 studien"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}